Centralized Omic REsource for TOPMed (CORE)

The National Institutes of Health's National Heart Lung and Blood Institute awarded this Master IDIQ for whole genome sequencing and omics services supporting the Trans-Omics for Precision Medicine (TOPMed) program on September 26, 2016, with a shared ceiling of $505 million. Ordering closed on September 25, 2021, and the vehicle is no longer available for new task-order placement.

The vehicle is fully executed. All 18 task orders issued under the IDIQ have obligated the combined potential value of $224.5 million in full, representing 100 percent of the combined task-order potential against the $505 million ceiling. The most recent task order was awarded on July 26, 2021, just before the ordering cutoff. Award activity peaked in 2018 and 2020, with four orders each year; ordering momentum declined to a single award in 2021.

Task orders procure whole genome sequencing, DNA methylation analysis, RNA expression profiling, metabolic profiling, and related omics services for heart, lung, blood, and sleep disorder research. Orders are priced firm fixed and range from approximately $951,700 to $36.4 million, with durations typically spanning one to five years. Task orders align to annual CORE program years, with most including performance extensions through 2024 or 2026.

Competition concentrates among three academic research institutions and genomics centers. The Broad Institute holds six orders valued at $75.7 million; University of Washington holds five orders valued at $65.7 million; Baylor College of Medicine holds four orders valued at $62.2 million. Washington University and New York Genome Center account for the remaining two awards. All 18 orders funded NHLBI exclusively, with no cross-agency ordering activity. All task orders are unrestricted; no set-aside designations apply.

Because the ordering period closed in September 2021, pursuit is limited to subcontracting or teaming with an incumbent prime, depending on whether any task orders remain active or subject to renewal modifications.

NHLBI's Trans-Omics for Precision Medicine (TOPMed) program seeks to discover factors that influence disease risk, identify subtypes of disease, and develop more targeted and personalized treatments. NHLBI's Centralized Omic REsource (CORE) program provides whole genome sequencing and other Omics measures including DNA methylation, RNA expression patterns and metabolic profiling for use with other phenotype and clinical outcome data from studies focused on HLBS disorders. Thus the program in conjunction with NHLBI's TOPMed Program, seeks to discover factors that influence disease risk, identify subtypes of disease, and develop more targeted and personalized treatments. In addition to providing a comprehensive view of genetic, molecular, and cellular architecture, the unprecedented rich data resource generated by CORE will be available to the scientific community stimulating innovative approaches to examine novel questions to address HLBS disorders.